Mild Cognitive Impairment (MCI): Pathogenesis and Treatments

참고문헌 (66)

1. Hebert LE, "Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050", Alzheimer Dis Assoc Disord, 15, pp.169~173 (2001)
2. Robertson D, "The prevalence of cognitive impairment in an elderly Canadian population", Acta Psychiatr Scand, 80, pp.303~309 (1989)
3. Graham JE, "Prevalence and severity of cognitive impairment with and without dementia in an elderly population", Lancet, 349, pp.1793~1796 (1997)
4. Morris JC, "Rubin disease", Arch Neurol, 58, pp.397~405 (2001)
5. Petersen RC, "Mild cognitive impairment: clinical characterization and outcome", Arch Neurol, 56, pp.303~308 (1999)
6. Petersen RC, "Current concepts in mild cognitive impairment", Arch Neurol, 58, pp.1985~1992 (2001)
7. Bozoki A, "Mild cognitive impairments predict dementia in nondemented elderly patients with memory loss", Arch Neurol, 58, pp.411~416 (2001)
8. Ritchie K, "Classification criteria for mild cognitive impairment: a population-based validation study", Neurology, 56, pp.37~42 (2001)
9. Brookmeyer R, , Am J Public Health, 88, pp.1337~1342 (1998)
10. Petersen RC, "Mild cognitive impairment: an overview", CNS Spectr, 13, pp.45~53 (2008)
11. Winblad B, "Long-term treatment of Alzheimer disease: efficacy and safety of acetylcholinesterase inhibitors", Alzheimer Dis Assoc Disord, 18(1), pp.s2~s8 (2004)
12. Kral VA, "Senescent forgetfulness: benign and malignant", Can Med Assoc J, 86, pp.257~260 (1962)
13. Crook T, "Age-associated memory impairment: proposed diagnostic criteria and measures of clinical change-Report of a National Institute of Mental Health Work Group", Dev Neuropsychol, 2, pp.261~276 (1986)
14. Levy R, "Aging-associated cognitive decline. Working party of the international Psychogeriatric association in cellaboration with the world health organization", Int Psychogeriatr, 6, pp.63~68 (1994)
15. Ganguli M, "Mild cognitive impairment, amnestic type: an epidemiologic study", Neurology, 63, pp.115~121 (2004)
16. Larrieu S, "Incidence and outcome of mild cognitive impairment in a population-based prospective cohort", Neurology, 59, pp.1594~1599 (2002)
17. Gauthier S, "Mild cognitive impairment", Lancet, 367, pp.1262~1270 (2006)
18. Daly E, "Predicting conversion to Alzheimer disease using standardized clinical information", Arch Neurol, 57, pp.675~680 (2000)
19. Corder EH, "Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families", Science, 261, pp.921~923 (1993)
20. Aggarwal NT, "Mild cognitive impairment in different functional domains and incidence Alzheimer’s disease", J Neurol Neurosurg Psychiatry, 76, pp.1479~1484 (2005)
21. Tierney MC, "T, Chi H. et al. A prospective study of the clinical utility of ApoE genotype in the prediction of outcome in patients with memory impairment", Neurology, 46, pp.149~154 (1996)
22. Petersen RC, "Apolipoprotein E status as a predictor of the development of Alzheimer’s disease in memory-impaired individuals", JAMA, 273, pp.1274~1248 (1995)
23. Jak AJ, "Differential cross-sectional and longitudinal impacts of APOE genotype on hippocampal volumes in nondemented older adults", Dement Geriatr Cogn Disord, 23, pp.382~389 (2007)
24. Klunk WE, "Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B", Ann Neurol, 55, pp.306~319 (2004)
25. Small GW, "FDDNP-PET binding differentiates MCI from dementia and increases with clinical progression", Alzheimer’s Dement, 2, pp.s318~s319 (2006)
26. Hansson O, "Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study", Lancet Neurol, 5, pp.228~234 (2006)
27. Lovell MA, "Oxidative damage in mild cognitive impairment and early Alzheimer’s disease", J Neurosci Res, 85, pp.3036~3040 (2007)
28. McGeer EG, "The importance of inflammatory mechanisms in Alzheimer disease", Exp Gerontol, 33, pp.371~378 (1998)
29. Richartz E, "Bartels M, Buchkremer G, et al. Diminished production of proinflammatory cytokines in patients with Alzheimer’s disease", Dement Geriatr Cogn Disord, 19, pp.184~188 (2005)
30. In t’ Veld BA, "Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease", N Engl J Med, 345, pp.1515~1521 (2001)
31. McGeer PL, "Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer disease: a review of 17 epidemiologic studies", Neurology, 47, pp.425~432 (1996)
32. Pasinetti GM, "Cyclo-oxygenase inhibitors and Alzheimer’s: are we well ADAPTed?", Lancet Neurol, 1, pp.403~404 (2002)
33. Galimberti D, "Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer’s disease", Neurobiol Aging, 27, pp.1763~1768 (2006)
34. Huberman M, "Correlation of cytokine secretion by mononuclear cells of Alzheimer patients and their disease stage", J Neuroimmunol, 52, pp.147`~152 (1994)
35. Tarkowski E, "Intrathecal inflammation precedes development of Alzheimer’s disease", J Neurol Neurosurg Psychiatry, 74, pp.1200~1205 (2003)
36. Magakia S, "Increased production of inflammatory cytokines in mild cognitive impairment", Exp Gerontol, 42, pp.233~240 (2007)
37. Guerreiro RJ, "Peripheral inflammatory cytokines as biomarkers in Alzheimer’s disease and mild cognitive impairment", Neurodegenerative Dis, 4, pp.406~412 (2007)
38. Lovell MA, "Oxidative damage in mild cognitive impairment and early Alzheimer’s disease", J Neurosci Res, 85, pp.3036~3040 (2007)
39. Keller JN, "Evidence of increased oxidative damage in subjects with mild cognitive impairment", Neurology, 64, pp.1152~1156 (2005)
40. Butterfield DA, "Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer’s disease", Neurobiol Dis, 22, pp.223~232 (2006)
41. Markesbery WR, "Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment", Ann Neurol, 58, pp.730~735 (2005)
42. Praticò D, "Lipid peroxidation and oxidative imbalance: early functional events in Alzheimer disease", J Alzheimer Dis, 6, pp.171~175 (2004)
43. Wang J, "Increased oxidative damage in nuclear and mitochondrial DNA in mild cognitive impairment", J Neurochem, 96, pp.825~832 (2006)
44. Lovell MA, "Oxidatively modified RNA in mild cognitive impairment", Neurobiol Dis, 29, pp.169~175 (2008)
45. Baldeiras I, "Peripheral oxidative damage in mild cognitive impairment and mild Alzheimer’s disease", J Alzheimer Dis, 15, pp.117~128 (2008)
46. Bermejo P, "Peripheral levels of glutathione and protein oxidation as markers in the development of Alzheimer’s disease from mild cognitive impairment", Free Radic Res, 42, pp.162~170 (2008)
47. Petersen RC, "Mild cognitive impairment clinical trials", Nat Rev Drug Discov, 2, pp.646~653 (2003)
48. Gauthier S, "Pharmacotherapy of mild cognitive impairment", Dialogues Clin Neurosci, 6, pp.391~395 (2004)
49. Petersen RC, "Vitamin E and donepezil for the treatment of mild cognitive impairment", N Engl J Med, 352, pp.2379~2388 (2005)
50. Aerssens J, "Raeymaekers P, Lilienfeld S, Geerts H, Konings F, Parys W. APOE genotype: no influence on galatamine treatment efficacy nor on the rate of decline in Alzheimer’s disease", Dement Geriatr Cogn Disord, 12, pp.69~77 (2001)
51. Feldman H, "Behavioral symptoms in mild cognitive impairment", Neurology, 62, pp.1199~1201 (2004)
52. Nagaraja D, "Randomized study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment", Am J Psychiatry, 158, pp.1517~1519 (2001)
53. Thal LJ, "A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment", Neuropsychopharmacology, 30, pp.1204~1215 (2005)
54. Rovio S, "Leisure-time physical activity at midlife and the risk of dementia and Alzheimer’s disease", Lancet Neurol, 4, pp.705~711 (2005)
55. Fratiqlioni L, "Influence of social network on occurrence of dementia: a community- based longitudinal study", Lancet, 355, pp.1315~1319 (2000)
56. Cui CA, "Macelignan attenuates LPS-induced inflammation and reduces LPS-induced spatial learning impairments in rats", Neurosci Lett, 448, pp.110~114 (2008)
57. Pepeu G, "Mild cognitive impairment: animal models", Dialogues in Clin Neurosci, 6, pp.369~377 (2004)
58. Gallagher M, "Effects of aging on the hippocampal formation in a naturally occurring animal model of mild cognitive impairment", Exp Gerontol, 38, pp.71~77 (2003)
59. Erickson CA, "The neurobiology of memory changes in normal aging", Exp Gerontol, 38, pp.61~69 (2003)
60. Rapp PR, "Recognition memory deficits in a subpopulation of aged monkeys resemble the effects of medial temporal lobe damage", Neurobiol Aging, 12, pp.451~486 (1991)
61. Rapp PR, "Evidence for task-dependent memory dysfunction in the aged monkey", J Neurosci, 9, pp.3568~3576 (1989)
62. Bachevalier J, "Behavioral changes in aged rhesus monkeys", Neurobiol Aging, 14, pp.619~621 (1993)
63. Tsukada H, "Effects of acute acetylcholinesterase inhibition on the cerebral cholinergic neuronal system and cognitive function: functional imaging of the conscious monkey brain using animal PET in combination with microdialysis", Synapse, 52, pp.1~10 (2004)
64. Castner SA, "Enhancement of working memory in aged monkeys by a sensitizing regimen of dopamine D1 receptor stimulation", J Neurosci, 24, pp.1446~1450 (2004)
65. Arnsten AF, "Goldman-Rakic PS. Analysis of alpha-2 adrenergic agonist effect on the delayed nonmatch-to-sample performance of aged rhesus monkeys", Neurobiol Aging, 11, pp.583~590 (1990)
66. Buccafusco JJ, "The effects of IDRA 21, a positive modulator of the AMPA receptor, on delayed matching performance by young and aged rhesus monkeys", Neuropharmacology, 46, pp.10~22 (2004)

관련 논문AI추천